History of Vaccines in Poultry: From Empirical Attenuation to Molecular Precision

Introduction

The domestication of gallinaceous birds for egg and meat production created ecological niches that favored the emergence and amplification of infectious pathogens. As poultry production intensified during the 20th century, viral, bacterial, and parasitic diseases imposed substantial economic burdens and threatened food security. Vaccination emerged as the primary intervention strategy, evolving from empirical attenuation methods to rationally designed molecular platforms. This article provides a comprehensive historical and technical review of poultry vaccine development, with emphasis on the biological mechanisms, immunological principles, and diagnostic frameworks that underpinned each generation of vaccine technology.

Foundations of Poultry Vaccinology: The First Generation (1920s 1960s)

Empirical Attenuation and the Birth of Live Vaccines

The earliest poultry vaccines were derived from field isolates passaged through unnatural hosts or embryonated eggs until virulence was reduced. This empirical approach was applied most notably to Newcastle disease virus (NDV). The lentogenic strains La Sota and B1, both isolated in the mid 20th century, became the backbone of global NDV control [1, 2, 37, 51, 52, 56, 68, 73, 77, 81]. These strains replicate in the respiratory tract without causing systemic disease, inducing both mucosal immunoglobulin A (IgA) and systemic immunoglobulin G (IgG) responses.

The biophysical mechanism of attenuation in NDV involves the acquisition of mutations at the fusion (F) protein cleavage site. Virulent NDV strains possess a multibasic cleavage site (RRQKRF) that is cleaved by ubiquitous furin-like proteases, enabling systemic replication. Lentogenic strains possess a monobasic cleavage site (GRQGRL) that requires trypsin-like proteases restricted to the respiratory and enteric tracts. This molecular distinction was elucidated decades after the vaccines were deployed.

Marek's Disease: The First Cancer Vaccine

Marek's disease virus (MDV), an alphaherpesvirus causing T cell lymphoma in chickens, presented a unique challenge [34, 35]. The development of the first vaccine against a naturally occurring cancer was a landmark achievement. The herpesvirus of turkeys (HVT), a non pathogenic related virus, was found to confer protective immunity when administered to day old chicks. HVT replicates persistently in the host without causing disease and induces cross protective immune responses against virulent MDV strains.

The immunological mechanism involves the activation of cytotoxic T lymphocytes (CTLs) targeting MDV specific antigens, particularly the meq oncoprotein and glycoproteins. The protective efficacy of HVT was later compromised by the emergence of very virulent plus (vv+) MDV strains, necessitating the development of bivalent vaccines combining HVT with the attenuated CVI988/Rispens strain [34, 35]. The Rispens strain is a naturally attenuated serotype 1 MDV that provides superior protection against highly virulent field strains.

The Golden Age of Viral Vaccine Development (1970s 1990s)

Infectious Bursal Disease: Immunosuppression and Vaccine Design

Infectious bursal disease virus (IBDV), a birnavirus targeting the bursa of Fabricius, causes profound immunosuppression in young chickens [3, 70, 78]. The history of IBDV vaccines illustrates the challenge of balancing immunogenicity with safety. The first generation vaccines were "classic" intermediate strains derived from the attenuated STC and D78 isolates. These strains replicate sufficiently in the bursa to induce protective immunity without causing significant bursal atrophy.

However, the emergence of very virulent IBDV (vvIBDV) strains in Europe during the 1980s necessitated "hotter" intermediate plus vaccines (e.g., 2512, Gumboral CT). These vaccines provide better protection against vvIBDV but carry a higher risk of bursal damage. The antigenic variation between classic and variant IBDV serotype 1 strains further complicated vaccine selection [3, 70, 78].

The molecular basis of IBDV attenuation involves mutations in the VP2 capsid protein that alter cell tropism and replication kinetics. VP2 is the major protective antigen and the target of neutralizing antibodies. Phylogenetic analyses have revealed the global dispersal of specific genotypes, including the recent transcontinental spread of Chinese genotype A2dB1b to South America [4].

Infectious Bronchitis Virus: Serotype Diversity and Vaccine Matching

Infectious bronchitis virus (IBV), a gammacoronavirus, exhibits extraordinary serotypic diversity due to the high mutation rate and recombination events affecting the S1 subunit of the spike glycoprotein [5, 40, 42, 45, 46, 59, 71, 76, 79, 80]. The S1 protein contains the receptor binding domain and the major neutralizing epitopes. Amino acid substitutions in the hypervariable regions of S1 can abrogate cross protection.

The history of IBV vaccination is characterized by a "chase" between emerging serotypes and available vaccines. The Massachusetts serotype (Mass 41) was the first attenuated vaccine and remains widely used. However, the emergence of serotypes such as 793/B (4/91), QX, D274, and VAR2 in different geographic regions necessitated the development of serotype specific vaccines [45, 46, 80].

A critical diagnostic challenge is the molecular differentiation of vaccine strains from field strains. Reverse transcription PCR targeting the S1 gene, followed by sequencing or genotype specific probes, is essential for outbreak investigations [40, 71]. The phenomenon of vaccine virus subpopulation variability further complicates interpretation [40].

Avian Metapneumovirus: A Neglected Pathogen

Avian metapneumovirus (aMPV) causes turkey rhinotracheitis and swollen head syndrome in chickens [6, 7, 8, 9]. The history of aMPV vaccines reflects a pattern of neglect and subsequent resurgence. Four subtypes (A, B, C, and D) have been identified, with subtype C containing both avian and human strains [6, 7]. The epidemiological history of aMPV in Europe, the Middle East, and North Africa reveals sustained circulation despite limited vaccination [8].

Live attenuated vaccines have been developed for subtypes A, B, and C. The mechanism of attenuation involves cold adaptation and passage in cell culture. Vaccine efficacy is often suboptimal due to the short duration of immunity and maternal antibody interference. Co infection with avian pathogenic Escherichia coli exacerbates clinical disease and complicates vaccine evaluation [9].

Avian Influenza: The Evolving Challenge of Vaccine Strain Selection

Highly pathogenic avian influenza (HPAI) H5N1 and H5Nx viruses have caused repeated outbreaks in poultry since the late 20th century [10, 11, 12, 13, 14, 15, 16, 17, 36, 38, 44, 50, 58, 65, 72]. The history of avian influenza (AI) vaccines is defined by the antigenic drift of the hemagglutinin (HA) glycoprotein, which necessitates periodic vaccine strain updates.

Inactivated whole virus vaccines, typically formulated as oil emulsion adjuvanted preparations, induce strong humoral immunity. The antigenic match between vaccine strain and circulating field strain is critical for efficacy. HA inhibition (HI) assays are used to measure antibody titers, but the correlation between HI titer and protection is not absolute [16, 36].

The emergence of the 2.3.4.4b clade of H5 subtype viruses in 2020 2021 illustrated the limitations of existing vaccines [14, 38]. Antigenic cartography revealed that older vaccine strains provided poor coverage against the new clade. This has driven interest in "universal" influenza vaccines targeting conserved regions of the HA stalk or the neuraminidase (NA) and matrix 2 (M2) proteins [36].

Messenger RNA (mRNA) based vaccines, which encode the HA protein and can be rapidly updated, represent a promising platform for poultry [36]. The lipid nanoparticle encapsulated mRNA is taken up by antigen presenting cells, translated into HA protein, and processed for major histocompatibility complex (MHC) class I and II presentation. This platform has not yet been widely deployed in poultry but has been evaluated in proof of concept studies.

Low pathogenicity avian influenza (LPAI) H9N2 viruses are enzootic in many regions and have caused substantial economic losses [17, 44, 50, 65, 72]. Vaccines for H9N2 are widely used in the Middle East, North Africa, and Asia, but antigenic drift and vaccine mismatches reduce efficacy.

Avian Reovirus: Genomic Plasticity and Vaccine Failure

Avian reovirus (ARV) causes viral arthritis and tenosynovitis in chickens and turkeys [18, 19, 20, 21, 74]. The virus has a segmented double stranded RNA genome, which facilitates reassortment and the generation of novel genotypes. The history of ARV vaccines in the United States and Europe illustrates the challenge of controlling a genetically plastic virus with live attenuated vaccines.

Phylodynamic analyses have reconstructed the dispersal patterns of ARV, revealing long distance transmission events likely mediated by trade in live poultry and contaminated equipment [19]. Turkey reovirus strains in the United States show distinct genomic signatures compared to chicken strains, indicating host adaptation [18].

Vaccine failure in ARV is often attributed to the emergence of variant field strains that are not neutralized by vaccine induced antibodies. Reverse transcription PCR targeting the sigma C (σC) and sigma B (σB) genes, followed by phylogenetic analysis, is used to monitor strain diversity and vaccine match [19, 74]. The accumulation of point mutations and reassortment events drives the molecular evolution of ARV [74].

Bacterial Vaccines: From Bacterins to Subunit Antigens

Mycoplasma synoviae and Mycoplasma gallisepticum

Mycoplasma infections in poultry cause chronic respiratory disease and synovitis [22, 66]. The history of vaccines for Mycoplasma synoviae includes the development of the live attenuated MS-H vaccine strain. A critical diagnostic need is the differentiation of vaccine strains from field strains in clinical samples. The European ring test evaluating molecular typing methods for M. synoviae demonstrated the feasibility of real time PCR based discrimination [22].

Mycoplasma gallisepticum (MG) vaccines include live attenuated strains (e.g., ts-11, 6/85) and bacterins. The ts-11 strain is temperature sensitive and replicates in the upper respiratory tract without causing disease. The mechanism of attenuation involves mutations that confer temperature sensitivity at 39°C (the body temperature of chickens), limiting replication to cooler tissues.

Pasteurella multocida and Fowl Cholera

Pasteurella multocida causes fowl cholera, a septicemic disease of chickens, turkeys, and waterfowl [23]. The history of P. multocida vaccines includes both bacterins (inactivated whole cell preparations) and live attenuated strains. The Clemson University (CU) strain is a live attenuated vaccine used in turkeys. However, safety concerns regarding reversion to virulence have driven interest in rationally attenuated mutants [23].

The molecular basis of attenuation in P. multocida involves deletion of virulence genes such as those encoding the capsule biosynthesis proteins or the lipopolysaccharide (LPS) biosynthesis enzymes. Deletion of the hyaE gene, involved in hyaluronic acid capsule synthesis, results in a non capsulated strain that is readily phagocytosed [23].

Salmonella and Erysipelothrix

Salmonella enterica serovars Gallinarum and Pullorum cause fowl typhoid and pullorum disease respectively [41, 55]. Live attenuated vaccines, such as the rough strain S. Gallinarum 9R, have been used for decades. The attenuation mechanism involves a rough LPS phenotype that reduces virulence while preserving immunogenicity.

Erysipelothrix rhusiopathiae causes erysipelas in turkeys and other birds [63, 75]. Bacterins and live attenuated vaccines are available. The molecular basis of protection involves antibodies targeting the surface protective antigen (Spa). Vaccine development for Erysipelothrix has been hindered by the antigenic diversity of Spa proteins among serotypes [75].

Parasitic and Fungal Vaccines

Histomonas meleagridis

Histomonas meleagridis causes blackhead disease in turkeys, a protozoal infection of the ceca and liver [24]. No commercially effective vaccine is currently available for routine use. Experimental vaccines have been developed using attenuated strains or recombinant antigens, but field efficacy has been inconsistent. Co infection with hemorrhagic enteritis virus complicates disease expression [24].

Coccidiosis Vaccines

Avian coccidiosis, caused by multiple species of Eimeria, is a major parasitic disease of chickens. The history of coccidiosis vaccines includes live virulent strains administered at low doses (to allow natural cycling and immunity) and live attenuated strains selected for precocious development (shorter prepatent period). The mechanism of protection is primarily cell mediated, involving CD4+ and CD8+ T cells in the intestinal mucosa.

The Interface of Vaccination and Diagnostics

Molecular Differentiation of Vaccine and Field Strains

The widespread use of live vaccines creates a diagnostic problem: distinguishing vaccine virus from field virus in clinical samples. Molecular diagnostic methods, including real time PCR with genotype specific probes, high resolution melting (HRM) analysis, and whole genome sequencing, are used for this purpose [22, 40, 71]. The European ring test for M. synoviae strain differentiation is an example of interlaboratory standardization [22].

Serological Monitoring

Enzyme linked immunosorbent assays (ELISA) are the primary tools for monitoring vaccine responses and detecting field infections [47, 61, 63]. Commercial ELISA kits detect antibodies against specific pathogens (e.g., IBDV, IBV, NDV, AIV). The interpretation of serological data requires knowledge of vaccination history, maternal antibody waning kinetics, and the potential for cross reactive antibodies from related viruses.

Maternally Derived Antibody Interference

Maternally derived antibodies (MDA), transferred via egg yolk, provide passive immunity to hatchlings but interfere with live vaccines [73]. The timing of vaccination is critical: vaccinating too early results in neutralization of the vaccine virus by MDA, while vaccinating too late leaves a window of susceptibility. The NDV vaccine vector platform is particularly affected by MDA interference [73].

flowchart TD
    A[Pathogen Emergence in Poultry], > B[Field Isolate Collection]
    B, > C{Vaccine Platform Selection}
    C, > D[Live Attenuated Vaccine]
    C, > E[Inactivated Vaccine Bacterin]
    C, > F[Subunit Recombinant Vaccine]
    C, > G[Vector Vaccine e.g. NDV HVT]
    C, > H[mRNA Vaccine]
    D, > I[Serial Passage in Eggs or Cell Culture]
    I, > J[Attenuation Confirmation <br/>Animal Challenge Studies]
    J, > K[Safety and Efficacy Trials]
    E, > L[Mass Culture Inactivation Adjuvant Formulation]
    L, > K
    F, > M[Antigen Identification Gene Cloning Expression]
    M, > K
    G, > N[Gene Insertion into Vector Backbone]
    N, > K
    H, > O[HA or Protective Antigen mRNA Sequence Design]
    O, > P[Lipid Nanoparticle Encapsulation]
    P, > K
    K, > Q{Regulatory Approval}
    Q, > R[Field Deployment]
    R, > S[Post Vaccination Surveillance]
    S, > T[Serological Monitoring ELISA HI]
    S, > U[Molecular Diagnostics PCR Genotyping]
    T, > V{Antigenic Match Assessment}
    U, > V
    V, > W[Vaccine Strain Update Needed]
    W, > C

Complex Pathogen Interactions and Vaccine Efficacy

Respiratory infections in poultry rarely involve a single pathogen. Co infections with viruses (IBV, aMPV, NDV, AIV) and bacteria (E. coli, Ornithobacterium rhinotracheale, Mycoplasma species) are common and influence vaccine efficacy [25, 9, 79]. A cross sectional study of upper respiratory tract infections in commercial free range layers revealed complex interactions between pathogens, with some combinations exacerbating disease severity and others showing antagonistic effects [25].

The presence of an immunosuppressive pathogen such as IBDV or chicken infectious anemia virus (CIAV) can impair the immune response to vaccination against other pathogens [26, 78]. The history of IBDV includes recognition that infection with vvIBDV in early life can compromise the efficacy of NDV and AIV vaccines [78].

Vaccine Platform Evolution and Future Directions

Vector Vaccines

Recombinant vector vaccines, particularly those based on HVT and NDV, allow the expression of protective antigens from multiple pathogens in a single construct [73, 75]. The HVT vector platform is widely used for bivalent vaccines protecting against MDV and either IBDV, AIV, or NDV. The advantages of vector vaccines include the absence of interference by MDA and the ability to deliver multiple antigens.

Reverse Genetics and Rationally Attenuated Vaccines

Reverse genetics systems, available for RNA viruses such as NDV, AIV, and IBV, allow the introduction of specific attenuating mutations into the viral genome. This approach enables the rational design of vaccine strains with defined genetic markers, facilitating molecular differentiation from field strains.

mRNA Vaccines

The success of mRNA vaccines for human SARS CoV 2 has spurred interest in this platform for veterinary applications [36]. For poultry, mRNA vaccines encoding the HA protein of AIV have been evaluated in proof of concept studies. The advantages of mRNA vaccines include rapid production (without the need for egg or cell culture), the ability to update the antigen sequence quickly, and the absence of infectious virus. Challenges include cost, thermostability, and the need for lipid nanoparticle formulation.

Conclusion

The history of vaccines in poultry is a narrative of continuous adaptation to pathogen evolution. From the empirical attenuation of NDV and MDV to the rational design of recombinant vector and mRNA vaccines, each generation of vaccine technology has addressed specific limitations of its predecessors. The fundamental challenge remains the antigenic and genetic plasticity of poultry pathogens, which requires sustained investment in surveillance, diagnostics, and vaccine strain update. The integration of molecular diagnostics with vaccine monitoring systems is essential for maintaining the efficacy of vaccination programs in the face of pathogen evolution.

References

[1] Choramo A, Debelo M, Tesfaye A et al. Serological detection of Newcastle disease virus in backyard poultry production system in Woliso District South West Shewa, Central Ethiopia. Immun Inflamm Dis. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38415972/

[2] Dharmayanti NI, Nurjanah D, Nuradji H et al. Newcastle disease virus: the past and current situation in Indonesia. J Vet Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38311318/

[3] Rautenschlein S, Schat KA, Saif YM. The History of Infectious Bursal Disease: The Second Period Between 1977 and 2005. Avian Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40643932/

[4] Tomás G, Techera C, Marandino A et al. Genomic characterization of infectious bursal disease virus in Argentina provides evidence of the recent transcontinental spread of Chinese genotype A2dB1b. Avian Pathol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38742448/

[5] Li H, Liu G, Zhou Q et al. Which strain of the avian coronavirus vaccine will become the prevalent one in China next? Front Vet Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37215473/

[6] Hatfield JS, Thielen BK, Goyal SM. Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review. Biomolecules. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41897288/

[7] Hatfield JS, Lauer DC, Goyal SM. History of Avian Metapneumovirus Subtype C in the United States. Avian Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41739606/

[8] Baston R, Tucciarone CM, Franzo G et al. A History of Neglect: Avian Metapneumovirus (aMPV) Epidemiology in Europe, the Middle East, and North Africa. Avian Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41739605/

[9] Salles GBC, Pilati GVT, Savi BP et al. Surveillance of Avian Metapneumovirus in Non-Vaccinated Chickens and Co-Infection with Avian Pathogenic Escherichia coli. Microorganisms. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38257889/

[10] Krammer F, Hermann E, Rasmussen AL. Highly pathogenic avian influenza H5N1: history, current situation, and outlook. J Virol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40145745/

[11] Prayugo AD, Subroto T, Arnafia W et al. Purification immunoglobulin yolk anti avian influenza H5N1 in poultry using hydrophobic interaction chromatography. Poult Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39778365/

[12] Li YT, Ko HY, Hughes J et al. From emergence to endemicity of highly pathogenic H5 avian influenza viruses in Taiwan. Nat Commun. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39472594/

[13] Islam A, Wille M, Rahman MZ et al. Phylodynamics of high pathogenicity avian influenza virus in Bangladesh identifying domestic ducks as the amplifying host reservoir. Emerg Microbes Infect. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39207215/

[14] Lin S, Chen J, Li K et al. Evolutionary dynamics and comparative pathogenicity of clade 2.3.4.4b H5 subtype avian influenza viruses, China, 2021-2022. Virol Sin. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38679333/

[15] Hiono T, Isoda N, Sakoda Y. [The current situation of H5 high pathogenicity avian influenza viruses in wild birds and mammals]. Uirusu. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/40024793/

[16] Alasiri A, Soltane R, Hegazy A et al. Vaccination and Antiviral Treatment against Avian Influenza H5Nx Viruses: A Harbinger of Virus Control or Evolution. Vaccines (Basel). 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38005960/

[17] Sagong M, Lee KN, Lee EK et al. Current situation and control strategies of H9N2 avian influenza in South Korea. J Vet Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36560837/

[18] Pamornchainavakul N, Vannatta JT, Singh VK et al. Connecting the Evolution and Spread of Turkey Reovirus Across the United States: A Genomic Perspective. Viruses. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41012612/

[19] Franzo G, Tucciarone CM, Faustini G et al. Reconstruction of Avian Reovirus History and Dispersal Patterns: A Phylodynamic Study. Viruses. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38793677/

[20] Palomino-Tapia V, Nickel L, Schlegel B et al. Review of Viral Arthritis in Canada. Avian Dis. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36715479/

[21] Pinto SC, Aleixo J, Camela K et al. Seroprevalence of infectious bronchitis virus and avian reovirus in free backyard chickens. *O

[22] Jimenez CM, Kreizinger Z, Gyuranecz M et al. European ring test on the differentiation of wild-type Mycoplasma synoviae and the MS-H vaccine strains in clinical samples. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42235157/

[23] Xu Q, Guan L, Xue Y et al. Natural Attenuated Vaccines for Pasteurella multocida. Biology (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41300259/

[24] Durairaj V, Nezworski J, Drozd M et al. Concurrent Histomonas meleagridis and Hemorrhagic Enteritis Virus Infection in a Turkey Flock with Recurrent History of Blackhead Disease. Avian Dis. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38687109/

[25] Rodrigo CH, Kulappu Arachchige SN, Bushell RN et al. Complex pathogen interactions in upper respiratory tract infections in commercial free-range layers: A cross-sectional study. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42190304/

[26] Pandor BR, Chauhan HC, Sharma KK et al. Molecular identification and Genogrouping of chicken infectious anaemia virus from commercial layer flocks of Gujarat, India. Virus Genes. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41484535/

[27] Yan W, Liu X, Jiang S et al. Emergence and characterization of historically extinct virulent genotype IV Newcastle disease virus in wild and domestic birds: genetic insights, pathogenicity, and vaccine efficacy. J Virol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41231019/

[28] Gao C, Yu H, Zhang W et al. Pathogen purification and genetic characterization of SPF BWEL chicken population. Poult Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40865380/

[29] Nakhaie M, Rukerd MRZ, Shahpar A et al. A Closer Look at the Avian Influenza Virus H7N9: A Calm before the Storm? J Med Virol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39601174/

[30] Abd El-Ghany WA, Algammal AM, Hetta HF et al. Gallibacterium anatis infection in poultry: a comprehensive review. Trop Anim Health Prod. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37889324/

[31] Becerra R, Nicholds J, Grogan K et al. Campylobacter hepaticus in the Production Environment and Stagnant Water as a Potential Source of C. hepaticus Causing Spotty Liver Disease in Free-Range Laying Hens in Georgia, United States. Avian Dis. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37140114/

[32] Napit R, Poudel A, Pradhan SM et al. Newcastle disease burden in Nepal and efficacy of Tablet I2 vaccine in commercial and backyard poultry production. PLoS One. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36897867/